Ostarine (MK-2866) vs RAD-140 vs LGD-4033: SARM Research Comparison Guide for 2026

Three names appear again and again in SARM literature: Ostarine (MK-2866), RAD-140, and LGD-4033. They surface constantly — in preclinical models, in investigational research programs, in academic reviews of androgen receptor pharmacology. And for good reason. These are, by most measures, the most extensively studied selective androgen receptor modulators currently under investigation.

But they’re not interchangeable. Not even close. Each compound has a distinct binding profile, a different selectivity signature, and a research history that points toward different applications. Understanding those differences isn’t just academic trivia — it shapes which compound is the right tool for a given study design.

This guide breaks down the research profile of each SARM individually, then puts them head-to-head on the metrics that matter most: binding affinity, tissue selectivity, and anabolic potency in preclinical models. All information here is strictly for research use only. None of the compounds discussed are approved for human use.

Understanding SARMs: Selective Androgen Receptor Modulators in Research

The androgen receptor (AR) is a ligand-activated transcription factor. When androgens like testosterone bind to it, a cascade of downstream effects follows — increased protein synthesis, bone mineral density changes, altered fat distribution, effects on the CNS, and more. That breadth is what makes classical androgens both powerful and difficult to use precisely in research.

SARMs were developed specifically to solve that problem. By engineering non-steroidal molecules that activate the AR selectively — preferentially in muscle and bone, while sparing androgenic tissues like the prostate — researchers hoped to isolate specific anabolic effects for study. It’s a conceptually elegant approach, and one that has generated a significant body of literature over the past two decades.

Ostarine, RAD-140, and LGD-4033 each represent a different point on the selectivity-potency spectrum. They bind the same receptor — but in meaningfully different ways, with meaningfully different downstream profiles. That’s what makes side-by-side comparison useful.

Worth noting before diving in: all three are research compounds only. They are not approved by any regulatory body for human use. All discussion here reflects findings from preclinical models, in vitro studies, and investigational research programs.

Ostarine (MK-2866): Research Profile

Ostarine — also known by its INN Enobosarm and its earlier designation GTx-024 — is the most extensively studied SARM in existence. Developed originally by GTx, Inc. (later in partnership with Merck), it set an early benchmark for what selective androgen receptor modulation could look like in practice. Decades of published research make it a reference point for the entire compound class.

Mechanism of Action

Ostarine binds the androgen receptor with a Ki of approximately 3.8 nM — solid affinity, though not the highest among the three compounds compared here. Its key structural feature is a selective binding conformation: upon binding, Ostarine induces a specific AR conformational change that differs from that produced by steroidal androgens. This differential coactivator recruitment is believed to underlie its tissue selectivity.

In preclinical models, Ostarine activates AR-dependent transcription in muscle and bone tissue with considerably less activity in androgenic tissues. That profile is what made it an early candidate for investigational programs targeting muscle wasting without the androgenic complications associated with anabolic steroids.

Muscle and Bone Research Findings

The research record here is deep. Animal models demonstrated significant anabolic effects at low concentrations — measurable increases in lean mass and improvements in physical function. Critically, those effects appeared at doses that produced minimal androgenic activity in prostate tissue, which was a key proof-of-concept finding for the SARM class overall.

Ostarine progressed further into formal investigational research than most SARMs. Phase II studies evaluated it in populations with muscle wasting associated with cancer cachexia, yielding data that has since been widely cited in SARM pharmacology literature. Results from those programs showed statistically significant improvements in lean body mass, making Ostarine the most clinically-proximate SARM in the published literature.

Bone research has also produced notable data. Studies examining bone mineral density in ovariectomized rat models showed Ostarine’s ability to maintain bone structure — a finding relevant to osteoporosis research frameworks.

Selectivity and Research Observations

Ostarine’s selectivity ratio is modest compared to RAD-140‘s extreme anabolic-to-androgenic numbers, but it’s well-characterized. That characterization is actually one of its research advantages — the compound’s behavior in various tissue types is known and reproducible, which makes it easier to use as a benchmark. In studies comparing SARM compounds, Ostarine frequently serves as the reference compound against which newer candidates are evaluated.

RAD-140 (Testolone): Research Profile

RAD-140 arrived later than Ostarine in the research timeline. Developed by Radius Health, it was designed from the outset to push the boundaries of anabolic selectivity — and by several measures, it succeeded. The compound exhibits one of the highest anabolic-to-androgenic ratios documented for any SARM, and its research applications extend beyond musculoskeletal biology into neuroscience. That’s a combination that has generated substantial scientific interest.

Mechanism of Action

RAD-140 binds the androgen receptor with high affinity and induces a receptor conformation distinct from both testosterone and other SARMs. What makes it unusual is what happens in different tissues: in muscle and bone, it functions as a full AR agonist. In the prostate, however, RAD-140 appears to act as an antagonist — actively suppressing androgenic activity in that tissue while driving anabolic effects elsewhere. This dual agonist/antagonist behavior depending on tissue context is a pharmacologically interesting finding that continues to attract research attention.

Anabolic Potency in Preclinical Studies

The numbers from RAD-140’s preclinical data are striking. In some animal models, the compound demonstrated an anabolic-to-androgenic ratio of approximately 90:1 relative to testosterone — meaning exceptional anabolic activity with minimal androgenic signal. Lean mass increases in castrated rat models were substantial. In direct comparisons with testosterone at equivalent doses, RAD-140 produced comparable or superior anabolic effects with far less androgenic activity in sensitive tissues.

That ratio has made RAD-140 a compound of particular interest for researchers studying muscle wasting models where androgenic complications would otherwise confound results. The ability to drive anabolic endpoints without proportional androgenic noise is genuinely useful from a study design perspective.

Neuroprotective Research Applications

This is where RAD-140 diverges most from its peers. A meaningful body of preclinical research has examined RAD-140’s potential in neuroprotection models. Androgen receptors are expressed in key regions of the brain, and AR activation has been associated with neuroprotective effects in several disease models. RAD-140 has shown activity in neural tissue in vitro and in animal models — including studies examining its effects in models relevant to Alzheimer’s disease and other neurodegenerative conditions.

This research direction is still early, but it distinguishes RAD-140 as a compound with potential utility outside the typical musculoskeletal framework that dominates SARM research.

LGD-4033 (Ligandrol): Research Profile

LGD-4033 — developed by Ligand Pharmaceuticals and later advanced by Viking Therapeutics under the name VK5211 — occupies a specific position in the SARM landscape: highest binding affinity of the three compounds discussed here, with some of the most compelling anabolic data from formal investigational research programs. It’s a potent compound by every measure, and its research history reflects that.

Mechanism of Action

LGD-4033 binds the androgen receptor with a Ki of approximately 1 nM — higher affinity than both Ostarine and, by most reported measures, RAD-140. That stronger receptor engagement translates to potent downstream AR activation in target tissues. Like the other SARMs in this comparison, it’s non-steroidal, which means it doesn’t carry the structural complications associated with steroid-based androgens.

Its selectivity profile shows strong agonism in muscle and bone with reduced activity in androgenic tissues. The binding characteristics have been studied in both recombinant receptor assays and intact cell models, with consistent results across systems.

Lean Mass Preservation Studies

The investigational research on LGD-4033 and lean mass is robust. Phase I investigational data showed dose-dependent increases in lean body mass in healthy male volunteers — a finding that attracted significant follow-on research interest. Even at low doses, the compound produced measurable anabolic effects. Animal models had already pointed in this direction: in castrated rat studies, LGD-4033 produced anabolic activity comparable to testosterone, but with substantially lower androgenic activity in the prostate.

Viking Therapeutics advanced the compound (as VK5211) into Phase II investigational research focused specifically on muscle loss following hip fracture — a population where rapid lean mass recovery is clinically meaningful. That research program generated data supporting the compound’s anabolic effects in a real-world muscle wasting context.

Bone Density Research

The hip fracture research program wasn’t just about muscle. Bone recovery was a key endpoint, and the Phase II data from Viking Therapeutics showed promising results on lean mass and functional recovery metrics in that population. Separate preclinical work has examined LGD-4033’s effects on bone mineral density in animal models, with findings suggesting meaningful activity at AR-expressing bone sites.

For researchers focused on osteoporosis models or bone remodeling studies, LGD-4033’s combination of high binding affinity and documented bone-relevant activity makes it a compound worth examining in that context.

Head-to-Head Comparison: Binding Affinity & Selectivity

Let’s get specific. Across the three key metrics that define SARM research utility — binding affinity, anabolic potency, and tissue selectivity — these compounds occupy distinct positions.

Binding Affinity: LGD-4033 leads here, with a Ki of approximately 1 nM. Ostarine follows at ~3.8 nM. RAD-140’s reported Ki varies across assay systems, but it consistently demonstrates high-affinity AR binding. In functional assays, all three effectively compete for receptor occupancy, but LGD-4033’s tighter binding translates to activity at lower concentrations in most models.

Anabolic Potency: RAD-140 edges ahead when looking at anabolic-to-androgenic ratios — the ~90:1 figure cited in some preclinical models is a standout number. LGD-4033 demonstrates high absolute anabolic potency. Ostarine is more moderate on both counts, which is actually part of its value as a research benchmark — it produces reliable, measurable effects without the extremes that complicate interpretation.

Tissue Selectivity: All three show AR selectivity favoring muscle and bone over androgenic tissues. RAD-140’s unique antagonist activity at the prostate AR is a distinctive feature. Ostarine’s selectivity is well-characterized across a wide tissue panel. LGD-4033 shows strong muscle/bone selectivity with a relatively well-defined androgenic tissue profile.

One practical note for researchers: selectivity data is assay-dependent and species-dependent. Numbers from rat models don’t always translate cleanly to primate models, and in vitro data from recombinant receptor assays doesn’t always predict behavior in intact tissue. Cross-referencing multiple data sources is essential.

Research Applications by Study Type

Choosing between these three compounds isn’t just about binding affinity charts. The relevant question is always: what does the study design demand? Each compound has a more natural fit with certain research contexts.

Muscle Wasting and Cachexia Models

All three compounds have been studied in muscle wasting contexts, but with different footprints. Ostarine has the deepest published record here — including Phase II investigational data from cancer cachexia programs. LGD-4033’s investigational data from hip fracture-related muscle loss is well-documented. RAD-140’s extreme anabolic-to-androgenic ratio makes it useful in models where androgenic tissue complications would otherwise confound results. For general muscle wasting models, all three are valid choices; for models requiring a benchmark compound with deep published data, Ostarine is the natural starting point.

Osteoporosis and Bone Research

LGD-4033 and Ostarine both have documented activity in bone density research. Ostarine has established data from ovariectomized animal models. LGD-4033’s Phase II data from the hip fracture program adds a layer of translational relevance. RAD-140 has less published bone-specific data but its high anabolic potency in musculoskeletal tissue makes it a candidate for exploratory bone research.

Hormonal and Endocrine Studies

SARM effects on the hypothalamic-pituitary-gonadal (HPG) axis are an area of active research. All three compounds show suppression of endogenous testosterone in animal models — a predictable consequence of AR activation. For studies examining HPG axis regulation, hormonal feedback, or endocrine disruption, that suppression profile is itself a research variable. RAD-140’s distinctive prostate antagonism also makes it interesting for androgen receptor studies in prostate biology and prostate cancer cell line research.

2026 Research Landscape

Where does SARM research stand heading into 2026? The honest answer is: the field is mature but still evolving. Early enthusiasm for SARMs as a clean solution to anabolic research challenges has been tempered by a more nuanced understanding of their complexity — selectivity is real but not absolute, and downstream effects in some tissue systems remain incompletely characterized.

That said, interest hasn’t dimmed. Ostarine remains the most-cited SARM in the academic literature, and sponsored research programs continue to investigate its utility in specific wasting conditions. RAD-140’s neuroprotection research thread is one of the more interesting emerging directions in the field. LGD-4033’s bone research data from the Viking Therapeutics program remains among the most compelling translational SARM data published.

Researchers in 2026 are also increasingly focused on comparative compound studies — moving beyond single-compound characterization toward understanding how different SARMs compare within the same model system. That’s exactly the kind of research context where a guide like this becomes practically useful.

Conclusion

Ostarine, RAD-140, and LGD-4033 are genuinely distinct compounds despite sharing a mechanism class. Ostarine is the gold standard for breadth of published data. LGD-4033 leads on binding affinity and has robust investigational-program data in muscle and bone. RAD-140 stands out for anabolic potency ratios and its unique applications in neuroprotection research.

No single compound is “best” in the abstract — the right choice depends entirely on the research question. What this comparison does offer is a clearer picture of where each compound’s strengths lie, which models they’ve been validated in, and how they differ on the parameters that matter for study design.

All three remain research-use-only compounds. None are approved for human use, and all findings discussed here apply strictly within the context of preclinical and investigational research. For researchers building study protocols or reviewing the existing literature, understanding these distinctions is foundational — and this guide aims to provide exactly that foundation.